Quick Answer
Ernexa Therapeutics Inc. reported Total Assets of $5.83 million for fiscal year 2025.
Ernexa Therapeutics Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $5.83M | +10.7% |
| 2024 | $5.27M | -89.3% |
| 2023 | $49.13M | +120.5% |
| 2022 | $22.28M | -29.3% |
| 2021 | $31.52M | +128.8% |
| 2020 | $13.78M | -2.5% |
| 2019 | $14.12M | -5.0% |
| 2018 | $14.86M | -10.3% |
| 2017 | $16.57M | -0.7% |
| 2016 | $16.70M | +1.7% |
| 2015 | $16.41M | -26.3% |
| 2014 | $22.27M | +44.1% |
| 2013 | $15.46M | +22.1% |
| 2012 | $12.66M | +8.7% |
| 2011 | $11.65M | -11.3% |
| 2010 | $13.12M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $6.17M | -20.0% | -18.6% |
| June 30, 2025 | $7.58M | -83.7% | +49.9% |
| March 31, 2025 | $5.06M | -89.8% | -4.0% |
| December 31, 2024 | $5.27M | -89.3% | -31.7% |
| September 30, 2024 | $7.72M | -85.2% | -83.4% |
| June 30, 2024 | $46.49M | -1.0% | -6.4% |
| March 31, 2024 | $49.66M | +228.7% | +1.1% |
| December 31, 2023 | $49.13M | +120.5% | -6.0% |
- Ernexa Therapeutics Inc. showed an increase of +10.7% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, Ernexa Therapeutics Inc.’s total assets has declined by 55.6% (from $13.12 million to $5.83 million).
- The most recent figure is from Ernexa Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: